Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
March 27, 2024 08:05 ET
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Nuclear Medicine Market revenue to surpass USD 20 Billion by 2033, says Research Nester
February 07, 2024 05:30 ET
|
Research Nester
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- The global nuclear medicine market size is predicted to expand at ~20% CAGR between 2023 and 2033. The market is projected to garner a revenue of USD 20...
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
July 13, 2023 07:30 ET
|
Aeterna Zentaris Inc
Highlights progress, recent developments and upcoming key milestonesCompany continues to build growing body of data across pipeline, advancing towards first in human studiesStrong financial position...
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
June 14, 2023 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
May 15, 2023 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting
July 06, 2022 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
April 25, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a neurodegenerative movement disorder ...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
March 29, 2022 08:00 ET
|
Aeterna Zentaris Inc
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 ...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
January 26, 2022 16:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the...